<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00802555</url>
  </required_header>
  <id_info>
    <org_study_id>ARQ 197-114</org_study_id>
    <nct_id>NCT00802555</nct_id>
  </id_info>
  <brief_title>Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>A Phase 1b Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ArQule, Inc. (a wholly owned subsidiary of Merck Sharp and Dohme, a subsidiary of Merck &amp; Co., Inc.)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, single-arm Phase 1b study designed to evaluate safety and tolerability of ARQ&#xD;
      197 in cirrhotic patients with HCC.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study designed to evaluate safety and tolerability of ARQ 197 in cirrhotic patients with HCC&#xD;
      who have received ≤2 prior systemic regimens for HCC, and whose liver disease severity is&#xD;
      categorized as Class A and B per Child-Pugh Classification.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of ARQ 197 when administered in cirrhotic patients diagnosed with HCC</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate time to disease progression (TTP), objective response rate (ORR), and disease control rate (DCR) in patients with HCC</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate dynamic changes of hepatocyte growth factor (HGF), vascular endothelial growth factor (VEGF), and soluble c-Met in patients' peripheral blood that are associated with ARQ 197 treatment</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Cirrhosis</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>ARQ 197</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARQ 197</intervention_name>
    <description>360 mg administered twice daily until disease progression, unacceptable toxicity, or other discontinuation criterion is met</description>
    <arm_group_label>ARQ 197</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent granted prior to initiation of any study-specific screening&#xD;
             procedures, given with the understanding that the patient has the right to withdraw&#xD;
             from the study at any time, without prejudice&#xD;
&#xD;
          -  18 year of age or older&#xD;
&#xD;
          -  Histologically or cytologically confirmed HCC (not required if: a hepatic lesion is&#xD;
             &gt;2cm in diameter , is suggestive of HCC at radiology and α-fetoprotein (AFP) is &gt; 200&#xD;
             mg/mL)&#xD;
&#xD;
          -  Barcelona Clinic Liver Cancer (BCLC) staging Category27 A, B or C that can not benefit&#xD;
             from treatments of established efficacy and/or higher priority&#xD;
&#xD;
          -  Cirrhotic status of Child-Pugh Class A and B without ascites or with slight ascites&#xD;
             that can be recognized only by imaging techniques and/or managed easily with diuretics&#xD;
             (e.g. 100 mg spironolactone per day and/or furosemide 40 mg/day)&#xD;
&#xD;
          -  Cirrhotic status confirmed by one of the following methods/evidence:&#xD;
&#xD;
          -  Biopsy&#xD;
&#xD;
          -  Endoscopy showing gastrointestinal tract varices&#xD;
&#xD;
          -  Evidence of portal hypertension on imaging studies such as dilated portal vein,&#xD;
             collateral circulation&#xD;
&#xD;
          -  ECOG PS ≤1&#xD;
&#xD;
          -  Not more than two prior systemic regimens for HCC and the last treatment must have&#xD;
             been completed ≥4 weeks prior to first dose of ARQ 197&#xD;
&#xD;
          -  Local or loco-regional therapy (i.e., surgery, radiation therapy, hepatic arterial&#xD;
             embolization, chemoembolization, radiofrequency ablation, percutaneous ethanol&#xD;
             injection, or cryoablation) must have been completed ≥4 weeks prior to first dose of&#xD;
             ARQ 197&#xD;
&#xD;
          -  Measurable disease as defined by revised Response Evaluation Criteria in Solid Tumors&#xD;
             (RECIST), version 1.1. Tumor lesions selected as target lesion(s) at baseline should&#xD;
             not have been previously treated with local therapy (naïve tumor lesion)&#xD;
&#xD;
          -  Adequate bone marrow, liver, and renal functions, defined as:&#xD;
&#xD;
          -  Platelet count ≥ 60 × 10^9/L&#xD;
&#xD;
          -  Hemoglobin ≥ 8.5 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1.5 × 10^9/L&#xD;
&#xD;
          -  Total bilirubin ≤ 3 mg/dL&#xD;
&#xD;
          -  Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 5 × upper limit of&#xD;
             normal (ULN)&#xD;
&#xD;
          -  Serum creatinine ≤1.5 × ULN&#xD;
&#xD;
          -  International normalized ratio (INR) ≤ 2.3 or PT ≤ 6.0 seconds above control. Patients&#xD;
             who are therapeutically anticoagulated with an agent such as coumadin or heparin are&#xD;
             allowed to participate provided that no prior evidence of underlying abnormality&#xD;
             exists in these parameters&#xD;
&#xD;
          -  Albumin ≥ 2.8 g/dL&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test performed within&#xD;
             seven days prior to the start of study drug&#xD;
&#xD;
          -  Male and female subjects of child-bearing potential must agree to use double-barrier&#xD;
             contraceptive measures, oral contraception, or avoidance of intercourse during the&#xD;
             study and for 90 days after last investigational drug dose received&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or concurrent cancer that is distinct from HCC in primary site or histology,&#xD;
             EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder&#xD;
             tumors (Ta, Tis &amp; T1). Any cancer curatively treated &gt;3 years prior to enrollment is&#xD;
             permitted&#xD;
&#xD;
          -  History of cardiac disease: congestive heart failure defined as Class II to IV per New&#xD;
             York Heart Association (NYHA) classification; active coronary artery disease (CAD);&#xD;
             previously diagnosed bradycardia or other cardiac arrhythmia, or uncontrolled&#xD;
             hypertension; myocardial infarction occurred within 6 months prior to study entry&#xD;
             (myocardial infarction occurred &gt; 6 months prior to study entry is permitted)&#xD;
&#xD;
          -  Active clinically serious infections defined as ≥ Grade 2 according to National Cancer&#xD;
             Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 3.0&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may, in the opinion&#xD;
             of the Investigator, interfere with the patient's participation in the study or&#xD;
             evaluation of the study results&#xD;
&#xD;
          -  Any condition that is unstable or which could jeopardize the safety of the patient and&#xD;
             his/her protocol compliance&#xD;
&#xD;
          -  Known HIV (human immunodeficiency virus) infection&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  History of liver transplant&#xD;
&#xD;
          -  Inability to swallow oral medications&#xD;
&#xD;
          -  Clinically significant gastrointestinal bleeding occurring ≤4 weeks prior to first&#xD;
             dose of ARQ 197&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bologna</city>
        <zip>15-40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>July 11, 2012</last_update_submitted>
  <last_update_submitted_qc>July 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HCC</keyword>
  <keyword>Cirrhotic Patients with Hepatocellular Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

